Clinical and demographic characteristics of patients with advanced HR+/HER2- breast cancer receiving ribociclib combined with endocrine therapy or combination chemotherapy in Russian clinical practice: second interim analysis of the ValerEE study dat
This article presents the results of the second interim analysis of data from the ValerEE study. The analysis examined a population of patients with advanced hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) breast cancer receiving either ribociclib combined with endocrine therapy (ET) or combination chemotherapy (CT) as first-line treatment in a real-world clinical setting in Russia. The study enrolled 100 % of the planned number of participants (N=333; 188 in the ribociclib plus ET group and 145 in the combination CT group). The groups were balanced regarding age (mean: 59.2 years), body mass index (mean: 27.7), menopausal status (75.7 % postmenopausal), and gender. Statistically significant differences between the groups were identified: the ribociclib plus ET group showed a higher proportion of patients with an ECOG performance status of 0 (20.7 % vs. 9.7 %, p=0.0208) and higher mean expression levels of estrogen receptors (7.4 vs. 6.9, p<0.001) and progesterone receptors (6.2 vs. 4.9, p<0.001); HER2-low status was also more frequent (38.8 % vs. 31.1 %, p=0.0344). Metastatic disease, including locoregional metastases, was more common in the chemotherapy group. The findings indicate that, in standard clinical practice in the Russian Federation, the selection of patients with HR+/HER2- recurrent/metastatic breast cancer for first-line therapy is based on clinical and biological characteristics. These differences must be taken into account when interpreting the comparative efficacy of these approaches.
Authors
- T.V. Vinogradova (ORCID: https://orcid.org/0009-0005-2322-7595)
- Гармарник Татьяна Валерьевна (ORCID: https://orcid.org/0009-0003-1865-4248)
- Liubov Yu Vladimirova (ORCID: https://orcid.org/0000-0002-4822-5044)
- Елена Владимировна Артамонова (ORCID: https://orcid.org/0000-0001-7728-9533)
- Е. V. Lymar (ORCID: https://orcid.org/0000-0002-6866-1425)
- Роман Сергеевич Жихорев (ORCID: https://orcid.org/0000-0003-2281-7380)
- Дергунов Александр Сергеевич (ORCID: https://orcid.org/0009-0000-5327-3991)
- Violetta Reznikov (ORCID: https://orcid.org/0009-0009-6413-3244)
- S.B. Belonogov (ORCID: https://orcid.org/0000-0002-5524-5537)
- E. V. Semenov (ORCID: https://orcid.org/0000-0002-4849-1940)
- Lyudmila Zhukova (ORCID: https://orcid.org/0000-0003-4848-6938)
- Воронкова Лия Михайловна (ORCID: https://orcid.org/0009-0003-5814-0575)
- Надежда Витальевна Леушина (ORCID: https://orcid.org/0009-0008-4386-5481)
- O.V. Mironov (ORCID: https://orcid.org/0000-0002-7549-7889)
Institutions
- Pirogov Russian National Research Medical University (RU)
- Moscow Clinical Scientific Center (RU)
- Krasnoyarsk State Medical University (RU)
- Russian Cancer Research Center NN Blokhin (RU)
- Clinical Hospital No. 8 (RU)
- Moscow Regional Scientific Research Clinical Institute. MF Vladimirsky (RU)
- Ministry of Health of the Russian Federation (RU)
- Novartis (United States) (US)
- Republican Oncological Clinical Dispensary (RU)
- Tyumen Regional Oncological Dispensary (RU)
- State Healthcare Institution "Regional Clinical Oncological Dispensary" (RU)
- Moscow City Oncology Hospital №62 (RU)
Publication Details
- Journal
- Medical alphabet
- Published
- 2026-11-17
- DOI
- https://doi.org/10.33667/2078-5631-2026-27-43-54
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00